Evvy raises $40M as it seeks to further women’s health research with vaginal microbiome data

We have spent decades building medical systems on the back of incomplete data. In the tech world, we call this a sampling bias problem. In healthcare, specifically women's health, it is a structural failure. Evvy’s recent $40 million Series B round, led by Catalio Capital Management, is less about the capital and more about the underlying thesis: biological data is the new raw infrastructure for personalized software.

The Data Gap in Female Healthcare

For a long time, clinical research treated the female body as a variation of the male body rather than a distinct biological system with its own unique metrics. This has created a massive technical debt in diagnostics. While we have spent billions mapping the human genome, we have largely ignored the microbiome communities that dictate health outcomes for half the population. Evvy is tackling this by focusing on the vaginal microbiome, a space that has been historically under-researched and underserved by traditional biotech.

As a founder, you have to look at this move through the lens of data acquisition. Evvy isn't just selling a test; they are building a proprietary database. In the AI era, the winner isn't the one with the best algorithm; it is the one with the highest quality, proprietary training data that no one else can scrape or buy.

Why Builders Should Watch the Bio-Data Space

Most crypto and AI founders spend their time worrying about tokenomics or GPU compute. But there is a massive opportunity in what I call the biological feedback loop. We are moving toward a world where your wearables and at-home tests inform your software experiences in real-time. If you are building in the wellness or longevity space, you are no longer just building an app; you are building an interface for biological data.

Evvy’s approach is a roadmap for how to verticalize a complex problem. They started with a direct-to-consumer testing kit. This gave them the initial data set and the revenue to prove product-market fit. Now, with $40 million in the bank, they are moving into the research and clinical phase. They are bridging the gap between a consumer gadget and a legitimate medical utility.

The Practicality of Personalized Medicine

We talk a lot about personalization in AI, but most of it is superficial—predicting what movie you want to watch or what email you want to write. Real personalization happens at the molecular level. By sequencing the microbiome, Evvy can provide specific recommendations that are grounded in hard science rather than generalized wellness trends. This is the kind of utility that creates long-term moat.

For the skeptical observer, the question is always about scale and privacy. Collecting biological data is a high-stakes game. When you handle this kind of information, you are taking on a level of responsibility that far exceeds typical SaaS products. Builders in this space need to be thinking about decentralized identity and zero-knowledge proofs as a way to protect this data, even if the current market isn't demanding it yet.

Investment Trends in a Hard Market

Securing a $40 million Series B in the current venture climate is no small feat. It tells us that investors are looking for businesses with tangible assets and defensible IP. The era of "growth at all costs" for simple software tools is cooling off. Capital is flowing toward companies that are solving hard, physical-world problems using digital-native tools.

Catalio Capital Management and the other participants in this round are betting on the long-tail value of research data. If Evvy can prove that their data leads to better outcomes for conditions like bacterial vaginosis or even fertility issues, they become an essential partner for pharmaceutical companies and insurers. That is where the real scale lives.

The Founder Perspective on Women's Health

For too long, "FemTech" was treated as a niche sub-category. That was a mistake. Half the population is not a niche. From a builder's perspective, this is one of the most underserved markets in the world. The challenges are significant—regulatory hurdles, long feedback loops, and high R&D costs—but the potential for impact is massive.

Evvy’s success shows that there is a path for startups to challenge the traditional healthcare establishment by going directly to the user. By empowering individuals with their own data, they are forcing the medical industry to catch up. This is a pattern we see over and over in technology: decentralization of information leads to a shift in power.

Takeaway for the Ecosystem

If you are building in the AI or bio-data space, take notes. Evvy didn't just build a better mousetrap; they identified a massive data void and built a business to fill it. The future of healthcare is not just about better pills; it is about better data loops. We are seeing the beginning of a shift where your biology becomes a set of readable, actionable metrics.

The most valuable companies of the next decade won't just move bits; they will translate biological reality into digital insights.

Stop looking for the next meme coin or chatbot wrapper. Look for the gaps in our collective knowledge of the human body. That is where the real value is being created.

Read the original at TechCrunch Startups →